List of Excipients in Branded Drug ASPERCREME ARTHRITIS

« Back to Dashboard

Generic Drugs Containing ASPERCREME ARTHRITIS

Company	Ingredient	NDC	Excipient
Chattem Inc	diclofenac sodium	41167-0571	AMMONIA
Chattem Inc	diclofenac sodium	41167-0571	CARBOMER HOMOPOLYMER TYPE C
Chattem Inc	diclofenac sodium	41167-0571	COCOYL CAPRYLOCAPRATE
Chattem Inc	diclofenac sodium	41167-0571	ISOPROPYL ALCOHOL
Chattem Inc	diclofenac sodium	41167-0571	MINERAL OIL
Chattem Inc	diclofenac sodium	41167-0571	POLYOXYL 20 CETOSTEARYL ETHER
Chattem Inc	diclofenac sodium	41167-0571	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in ASPERCREME ARTHRITIS?

# Of NDCs	Excipient
2	AMMONIA
2	CARBOMER HOMOPOLYMER TYPE C
2	COCOYL CAPRYLOCAPRATE
2	ISOPROPYL ALCOHOL
2	MINERAL OIL
2	POLYOXYL 20 CETOSTEARYL ETHER
2	PROPYLENE GLYCOL

Aspercreme Arthritis Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Aspercreme Arthritis is a topical diclofenac sodium 1% gel for temporary relief of arthritis pain. Its current excipient platform is a conventional hydroalcoholic, carbomer-thickened gel containing propylene glycol, mineral oil, a surfactant, an emollient, ammonia solution, and purified water. The commercial opportunity is less likely to come from basic ingredient substitution than from differentiated delivery, improved skin tolerability, dose accuracy, packaging, and line extensions that preserve diclofenac's established regulatory position.

What is Aspercreme Arthritis and which excipients does it contain?

Aspercreme Arthritis contains diclofenac sodium 1% as the active pharmaceutical ingredient. The product is intended for topical use on joints affected by osteoarthritis, including the hand, wrist, elbow, foot, ankle, and knee. It is not intended for use on the spine, hip, or shoulder under the standard consumer labeling framework. [1]

The public product labeling identifies the following inactive ingredients:

Excipient	Primary formulation function
Carbomer homopolymer type C	Gelling and viscosity control
Cocoyl caprylocaprate	Emollient and skin-feel modifier
Isopropyl alcohol	Solvent, penetration aid, and evaporation modifier
Mineral oil	Emollient and occlusive skin-conditioning agent
Polyoxyl 20 cetostearyl ether	Nonionic surfactant and solubilizer
Propylene glycol	Cosolvent, humectant, and penetration enhancer
Purified water	Vehicle
Ammonia solution	Neutralizer and pH adjustment agent

The formulation architecture is consistent with a water-based topical gel that balances diclofenac solubilization, spreadability, drying time, and skin contact. Carbomer provides the gel structure after neutralization. Isopropyl alcohol and propylene glycol affect solvent capacity and dermal delivery. Mineral oil and cocoyl caprylocaprate reduce the dry or sticky feel associated with high-water gels. Polyoxyl 20 cetostearyl ether supports dispersion of lipophilic components. [1]

How does the Aspercreme Arthritis excipient system support product performance?

The excipient system addresses four commercial performance requirements: uniform application, acceptable skin feel, drug release, and consumer adherence.

Viscosity and dose distribution

Carbomer is the principal rheology modifier. A well-controlled carbomer concentration produces a gel that remains on the application site but spreads under light rubbing. Excessive viscosity can reduce coverage and increase the amount consumers apply. Low viscosity can increase runoff, transfer to clothing, and dosing variability.

For a diclofenac gel, rheology is a critical quality attribute because the consumer applies a measured quantity by joint size rather than by a metered pump. The formulation must support reproducible spreading across a defined surface area.

Skin feel and drying time

Isopropyl alcohol promotes rapid drying and can reduce residual greasiness. Propylene glycol prolongs wet contact and can improve solvent performance, but high levels may increase tackiness or irritation in sensitive users. Mineral oil and cocoyl caprylocaprate counterbalance alcohol-related dryness and improve lubricity.

This creates a formulation tradeoff. Increasing volatile solvent content can improve drying time but may worsen sting or dryness. Increasing emollient content can improve comfort but may create an oily residue and reduce consumer acceptance.

Drug release and dermal delivery

Diclofenac sodium is water-soluble, but the finished gel also contains partially lipophilic excipients. The solvent and surfactant balance can affect drug partitioning from the vehicle into the stratum corneum. Changes to propylene glycol, alcohol, surfactant, carbomer grade, or pH can alter viscosity, release, skin permeation, and local tolerability.

A substitute formulation cannot be assessed only by assay and appearance. It needs comparative characterization of:

• Diclofenac content and uniformity
• pH
• Viscosity and yield stress
• In vitro drug release
• In vitro permeation through human or synthetic membranes
• Drying time
• Residue and transfer
• Microbial quality and preservative performance
• Skin irritation and sensitization

FDA guidance for topical dermatological products emphasizes product quality, drug release, and performance testing because locally acting products may not be adequately characterized by systemic pharmacokinetics alone. [3]

What formulation patents could protect an Aspercreme Arthritis strategy?

The basic excipient list is unlikely to create strong standalone protection. Individual ingredients such as carbomer, propylene glycol, mineral oil, and isopropyl alcohol are widely used and generally available from multiple suppliers. The protectable value lies in the combination, process, performance profile, or packaging system.

Potential claim areas include:

1. A diclofenac gel with a defined viscosity range and pH.
2. A composition with specified ratios of alcohol, propylene glycol, emollient, and surfactant.
3. A low-residue or fast-drying formulation with defined transfer characteristics.
4. A formulation that improves diclofenac delivery while reducing skin irritation.
5. A composition using a specific carbomer grade or neutralization process.
6. A preservative-free or low-preservative package with validated microbiological protection.
7. A metered-dose dispenser that delivers a reproducible amount per actuation.
8. A unit-dose or single-use format that limits contamination and improves portability.
9. A formulation designed to reduce staining, greasiness, or transfer to textiles.
10. A manufacturing process that improves drug uniformity or controls particle size and dispersion.

Patent strength would depend on the claims' measurable boundaries and the prior art. A broad claim covering "diclofenac, carbomer, alcohol, and propylene glycol" would face substantial validity risk because similar topical systems are well known. Narrow claims tied to a defined performance result, manufacturing step, or device interaction could offer stronger differentiation.

What is the FDA regulatory status of Aspercreme Arthritis?

Aspercreme Arthritis is a nonprescription topical diclofenac product marketed for arthritis pain. Diclofenac sodium topical gel 1% entered the U.S. OTC market through an FDA-approved prescription-to-nonprescription pathway for arthritis pain products. The FDA-approved OTC precedent is associated with Voltaren Arthritis Pain, which established the consumer labeling and usage framework for topical diclofenac 1%. [2]

Diclofenac topical gel is not a simple monograph ingredient comparable to menthol or methyl salicylate. A new product or formulation change can require an approved drug application, an applicable abbreviated pathway, or another FDA-recognized regulatory basis. The regulatory route depends on the proposed formulation, reference product, labeling, dosage form, and whether the change affects performance or clinical use.

Excipient changes can trigger regulatory work when they alter:

• Drug release
• Skin permeation
• Local exposure
• Product viscosity
• Application quantity
• Stability
• Microbial control
• Irritation profile
• Container-closure performance

The FDA Inactive Ingredient Database can support excipient selection, but prior use at a particular route and concentration does not eliminate the need to demonstrate product quality and performance. [4]

How many patents cover Aspercreme Arthritis?

The relevant patent estate has to be separated into four categories:

Patent category	Relevance to Aspercreme Arthritis
Active-ingredient patents	Limited for diclofenac sodium, an established compound
Formulation patents	Potentially relevant to gel composition, release, and tolerability
Method-of-use patents	Potentially relevant to arthritis indications or dosing instructions
Packaging and device patents	Relevant to dispensers, dose control, and contamination control

The Orange Book is the principal public source for patents and exclusivity associated with approved drug applications. Patent coverage can differ between the reference product, authorized generics, private-label products, and independently approved products. Orange Book listings also do not capture every patent that could be asserted in a commercial dispute. [5]

For a commercial excipient program, the key diligence questions are whether the proposed formulation reads on an active formulation patent, whether a supplier owns relevant composition or process rights, and whether a device patent controls the intended package. Ingredient procurement alone does not provide freedom to operate.

When does Aspercreme Arthritis lose exclusivity?

The product's commercial protection is unlikely to depend on a single expiration date. The relevant dates may include:

• NDA patents listed in the Orange Book
• Pediatric exclusivity, if granted
• Regulatory exclusivity associated with the approved application
• Formulation or process patents
• Packaging and dispensing-device patents
• Trademark rights in the Aspercreme brand
• Supplier agreements and manufacturing rights

A generic competitor may challenge listed patents through a Paragraph IV certification. A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman framework and, if litigation is timely filed, may create a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and court developments. [6]

For topical diclofenac, the more material entry barrier may be regulatory comparability and commercial execution rather than active-ingredient exclusivity. A competitor still needs a formulation that meets quality, performance, labeling, and manufacturing requirements. A product with a technically acceptable formulation may remain commercially weak if it has poor spreadability, an unpleasant odor, high transfer, or an inconvenient container.

What excipient opportunities could improve Aspercreme Arthritis?

Low-irritation formulation

A lower-irritancy system could reduce the sting and dryness associated with alcohol-containing topical gels. Opportunities include:

• Lowering volatile alcohol content
• Rebalancing propylene glycol
• Using alternative emollients
• Modifying pH within the product's validated performance range
• Replacing or reducing surfactant exposure
• Adding skin-conditioning excipients with established topical safety

The risk is that improved skin comfort may reduce drying speed, alter drug release, or make the product feel greasy.

Fast-drying, low-transfer gel

A low-transfer product could appeal to consumers who apply topical medication during the day. The commercial target is a gel that dries quickly without leaving a visible film or oily residue.

Potential approaches include:

• Optimizing alcohol-to-water ratio
• Using volatile co-solvents
• Reducing high-residue emollients
• Adjusting carbomer concentration
• Using a film-forming system with controlled deposition

Claims should focus on measurable outcomes such as drying time, residue mass, textile transfer, or rub-off resistance.

Non-greasy emulsion-gel

An emulsion-gel could improve sensory performance while retaining dermal delivery. This approach may use a lower-oil internal phase, a different nonionic emulsifier, or a structured lipid system. It could support a premium product tier but would increase development complexity and the risk of instability.

Preservative-minimized packaging

A preservative-minimized system could use an airless pump, unit-dose sachet, or one-way valve to reduce repeated microbial exposure. The package could also improve dose reproducibility and limit direct finger contact.

The package is part of the product's regulatory and patent strategy. Changes to the container can affect extractables, leachables, stability, dose delivery, and in-use microbiological protection.

Moisturizing arthritis gel

A consumer-oriented version could emphasize skin comfort through a controlled level of humectant and emollient. The product cannot imply treatment of damaged skin or unrelated dermatological conditions without supporting regulatory evidence. The claim strategy should remain tied to arthritis pain relief and acceptable topical use.

Which companies could challenge the commercial position?

Competition can come from several groups:

• Branded topical analgesic manufacturers
• Generic diclofenac gel manufacturers
• Retailers offering store-brand topical diclofenac
• Private-label consumer-health companies
• Compounding pharmacies, within applicable legal limits
• Alternative topical NSAID developers
• Non-NSAID analgesic products using menthol, lidocaine, capsaicin, or salicylates

The strongest direct competitors are other diclofenac sodium 1% gels. They can compete on price, tube size, pump format, label clarity, and consumer familiarity. Indirect competitors can avoid diclofenac patent issues but compete for the same arthritis-pain use occasion.

There is no biosimilar risk because Aspercreme Arthritis contains a small-molecule NSAID rather than a biologic. The relevant entry risks are generic substitution, private-label erosion, formulation copying, and channel-specific pricing.

How does Aspercreme Arthritis compare with competing topical pain products?

Product category	Main active	Excipient opportunity	Main commercial advantage
Diclofenac 1% gel	Diclofenac sodium	Delivery, sensory profile, dosing package	Established arthritis indication
Menthol products	Menthol	Cooling sensation and evaporation	Immediate sensory feedback
Lidocaine products	Lidocaine	Local anesthetic delivery and skin tolerance	Numbing effect
Capsaicin products	Capsaicin	Controlled irritation and adhesion	Non-NSAID mechanism
Salicylate products	Methyl salicylate or related agents	Odor, skin feel, and absorption control	Familiar counterirritant positioning

Diclofenac has a stronger product-specific arthritis positioning than many counterirritants. Its disadvantages include greater regulatory complexity, NSAID-related labeling restrictions, and the need to manage consumer expectations around delayed or cumulative pain relief.

What licensing and partnership opportunities exist?

Excipient suppliers can pursue licensing or co-development opportunities in five areas:

1. Novel low-irritation solvent systems.
2. High-performance carbomer or alternative rheology platforms.
3. Airless or metered-dose topical dispensers.
4. Low-transfer and fast-drying delivery systems.
5. Comparative performance packages supporting regulatory submissions.

The most valuable licensing assets would combine composition claims with data showing improved drug release, skin tolerability, transfer resistance, or dose uniformity. A commodity excipient supply agreement is less defensible than a package combining proprietary excipient grades, process know-how, analytical methods, and regulatory support.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers include control of carbomer hydration, neutralization, air entrainment, drug uniformity, viscosity drift, microbial control, and compatibility with the container. Scale-up can change gel structure even when the nominal composition remains unchanged.

Critical process controls include:

• Order of ingredient addition
• Mixing energy and shear
• Hydration time
• Neutralization endpoint
• Temperature control
• Deaeration
• Filling speed
• Tube or pump compatibility

The strongest manufacturing IP may protect a process that produces a defined rheological or release profile. Trade secrets can protect mixing sequence, deaeration, and scale-up parameters, but trade-secret protection is weaker against independent development than a well-drafted patent.

Key Takeaways

• Aspercreme Arthritis uses a conventional diclofenac sodium 1% hydroalcoholic gel platform.
• Carbomer controls gel structure; propylene glycol and isopropyl alcohol support solvent performance and dermal delivery.
• Mineral oil and cocoyl caprylocaprate improve skin feel but can increase residue or transfer.
• The best commercial opportunities are low-irritation, fast-drying, low-transfer, metered-dose, and preservative-minimized products.
• Broad excipient-combination claims face prior-art risk. Narrow performance, process, and device claims are more defensible.
• Generic and private-label competition presents greater practical risk than biosimilar competition.
• Orange Book patents, formulation patents, method-of-use patents, device rights, trademarks, and supplier agreements should be analyzed separately.
• A formulation change can alter drug release, permeation, stability, microbial control, and regulatory status.

FAQs

Can Aspercreme Arthritis be reformulated without changing the active ingredient?

Yes, but an excipient change can affect product performance, stability, skin exposure, and regulatory comparability. The change must be evaluated as a drug-product modification rather than as a simple cosmetic substitution.

Which excipient is most important for diclofenac gel performance?

Carbomer is central to viscosity and spreadability, but solvent balance is equally important because propylene glycol, isopropyl alcohol, water, and surfactant levels influence drug release and skin delivery.

Is a preservative-free Aspercreme Arthritis product commercially viable?

It may be viable if the package limits contamination and the product passes in-use microbiological testing. An airless pump or unit-dose package would be more suitable than a conventional repeatedly opened container.

Could a pump package create patent value?

Yes. A pump can support claims directed to delivered dose, valve operation, contamination control, residual product, or compatibility with a viscous diclofenac gel.

Is diclofenac 1% gel subject to biosimilar competition?

No. Diclofenac is a small-molecule drug. Competition arises through generic or private-label drug products, branded topical analgesics, and alternative pain-relief mechanisms.

References

1. DailyMed. (n.d.). Diclofenac sodium topical gel 1%: Drug facts and prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2020). FDA approves first over-the-counter topical nonsteroidal anti-inflammatory drug for arthritis pain.
3. U.S. Food and Drug Administration. (2022). Draft guidance for industry: In vitro release test studies for topical dermatological drug products submitted in ANDAs.
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).